BPC-157 vs IGF-1 LR3 for dogs
The short answer
These sit at opposite ends of the risk spectrum covered on this site. BPC-157 has a dedicated preclinical toxicity evaluation covering dogs that reported no serious toxicity, and carries no cancer contraindication. IGF-1 LR3 can cause clinically significant hypoglycaemia, is firmly contraindicated in any dog with malignancy, and requires mandatory off-cycling. They also target different problems: BPC-157 is studied for tissue repair, IGF-1 LR3 for muscle mass. For post-surgical recovery where both muscle loss and tissue repair are in play, BPC-157 is the far more conservative starting point, and IGF-1 LR3 only becomes a reasonable discussion once malignancy has been excluded.
Side by side
| BPC-157 | IGF-1 LR3 | |
|---|---|---|
| Evidence grade | Emerging evidence | Preliminary / in vitro only |
| Safety profile | No serious toxicity in a preclinical evaluation that included dogs | Hypoglycaemia risk; requires glucose monitoring |
| Cancer contraindication | None established | Contraindicated with active or suspected cancer |
| Target | Tissue repair and gut protection | Muscle mass and protein synthesis |
| Cycling | Continuous within the protocol window | Mandatory 4-week off-cycle, maximum 3 cycles |
| Full profile | BPC-157 for dogs | IGF-1 LR3 for dogs |
Safety at a glance
BPC-157
BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.
Is BPC-157 safe for dogs? →IGF-1 LR3
IGF-1 LR3 demands more caution than anything else on this site apart from the investigational oncology compounds. Two risks are concrete rather than theoretical: it can lower blood glucose enough to cause tremors or collapse, and because IGF-1 signalling drives cell proliferation it is contraindicated in any dog with known or suspected cancer. The mandatory four-week off-cycle exists to let receptor sensitivity recover. Canine evidence is Level V — mechanistic and extrapolated, not clinical.
Is IGF-1 LR3 safe for dogs? →Common questions
Which is better for dogs, BPC-157 or IGF-1 LR3?+
These sit at opposite ends of the risk spectrum covered on this site. BPC-157 has a dedicated preclinical toxicity evaluation covering dogs that reported no serious toxicity, and carries no cancer contraindication. IGF-1 LR3 can cause clinically significant hypoglycaemia, is firmly contraindicated in any dog with malignancy, and requires mandatory off-cycling. They also target different problems: BPC-157 is studied for tissue repair, IGF-1 LR3 for muscle mass. For post-surgical recovery where both muscle loss and tissue repair are in play, BPC-157 is the far more conservative starting point, and IGF-1 LR3 only becomes a reasonable discussion once malignancy has been excluded.
Can BPC-157 and IGF-1 LR3 be used together in dogs?+
Combined protocols using both compounds appear in the literature, and they are more often studied together than as alternatives. Any combination increases the difficulty of attributing an adverse effect to a specific compound, so combining should be a deliberate decision made with your veterinarian rather than a default.
Which has better evidence in dogs, BPC-157 or IGF-1 LR3?+
BPC-157 is graded emerging evidence with 6 cited studies; IGF-1 LR3 is graded preliminary evidence with 2 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
- 7.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16024511
- 8.Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 2011. PMID 21354439
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.